BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 16831224)

  • 1. Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy?
    Perez-Plasencia C; Duenas-Gonzalez A
    Mol Cancer; 2006 Jul; 5():27. PubMed ID: 16831224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetics in cancer: targeting chromatin modifications.
    Ellis L; Atadja PW; Johnstone RW
    Mol Cancer Ther; 2009 Jun; 8(6):1409-20. PubMed ID: 19509247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; CalabrĂ² L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance.
    Wilting RH; Dannenberg JH
    Drug Resist Updat; 2012; 15(1-2):21-38. PubMed ID: 22356866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA methylation and histone modifications in patients with cancer: potential prognostic and therapeutic targets.
    Herranz M; Esteller M
    Methods Mol Biol; 2007; 361():25-62. PubMed ID: 17172706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical application of targeting cancer through histone acetylation and hypomethylation.
    Gilbert J; Gore SD; Herman JG; Carducci MA
    Clin Cancer Res; 2004 Jul; 10(14):4589-96. PubMed ID: 15269129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs.
    Baker EK; Johnstone RW; Zalcberg JR; El-Osta A
    Oncogene; 2005 Dec; 24(54):8061-75. PubMed ID: 16091741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.
    Teodoridis JM; Strathdee G; Brown R
    Drug Resist Updat; 2004; 7(4-5):267-78. PubMed ID: 15533764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetics in cancer stem cells.
    Toh TB; Lim JJ; Chow EK
    Mol Cancer; 2017 Feb; 16(1):29. PubMed ID: 28148257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular targets for epigenetic therapy of cancer.
    Humeniuk R; Mishra PJ; Bertino JR; Banerjee D
    Curr Pharm Biotechnol; 2009 Feb; 10(2):161-5. PubMed ID: 19199948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA demethylating agents and epigenetic therapy of cancer.
    Mani S; Herceg Z
    Adv Genet; 2010; 70():327-40. PubMed ID: 20920754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting DNA methylation in cancer.
    Szyf M
    Bull Cancer; 2006 Sep; 93(9):961-72. PubMed ID: 16980240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets.
    Chekhun VF; Lukyanova NY; Kovalchuk O; Tryndyak VP; Pogribny IP
    Mol Cancer Ther; 2007 Mar; 6(3):1089-98. PubMed ID: 17363502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using Epigenetic Therapy to Overcome Chemotherapy Resistance.
    Strauss J; Figg WD
    Anticancer Res; 2016 Jan; 36(1):1-4. PubMed ID: 26722021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chromatin epigenetic modifications in cancer generation].
    Arenas-Huertero F; Recillas-Targa F
    Gac Med Mex; 2002; 138(6):547-55. PubMed ID: 12532619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer's epigenetic drugs: where are they in the cancer medicines?
    Ghasemi S
    Pharmacogenomics J; 2020 Jun; 20(3):367-379. PubMed ID: 31819161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetically Active Drugs Inhibiting DNA Methylation and Histone Deacetylation.
    Chistiakov DA; Myasoedova VA; Orekhov AN; Bobryshev YV
    Curr Pharm Des; 2017; 23(8):1167-1174. PubMed ID: 27774908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
    Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
    Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA methylation: an epigenetic pathway to cancer and a promising target for anticancer therapy.
    Worm J; Guldberg P
    J Oral Pathol Med; 2002 Sep; 31(8):443-9. PubMed ID: 12220350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic mechanisms in AML - a target for therapy.
    Oki Y; Issa JP
    Cancer Treat Res; 2010; 145():19-40. PubMed ID: 20306243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.